Revvity Inc. reported first‑quarter 2026 results, posting adjusted earnings per share of $1.06 versus consensus of $1.02, a $0.04 or 3.9% beat. The company also delivered revenue of $711.1 million, topping the $705.2 million estimate by $5.9 million (0.8% beat). These figures were released on May 5, 2026.
Revenue growth of 7% year‑over‑year was driven by a 3% organic increase and a 6% pro‑forma lift after excluding the China Immunodiagnostics business. Life Sciences revenue rose to $361.8 million, up 6% YoY, while Diagnostics revenue reached $349.3 million, up 8% YoY, supported by strong reproductive‑health demand.
Despite the top‑line gains, adjusted operating margin contracted to 23.6% from 25.6% a year earlier, and adjusted gross margin fell to 59.5% from 61.7%. The decline reflects higher investment costs, an unfavorable product mix, and the impact of an extra week in the reporting period, all of which pressured profitability.
Management highlighted continued demand for its Signals software platform and new product launches such as Signals BioDesign and the Opera Phenix OptiQ system. The company also announced the divestiture of its China Immunodiagnostics business, which represented about 6% of 2025 revenue, to sharpen focus on higher‑margin opportunities.
Revvity’s full‑year guidance remains unchanged, with revenue projected between $2.81 billion and $2.84 billion and adjusted EPS guidance of $5.20 to $5.30. The steady outlook signals management confidence in sustaining growth while navigating margin pressures and the strategic portfolio shift.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.